Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections
Authors:
- Anton PetcherskiAnton Petcherski
- Brett M TingleyBTBrett M Tingley
- Andrew MartinAMAndrew Martin
- Sarah AdamsSASarah Adams
- Alexandra J BrownsteinABAlexandra J Brownstein
- Ross A SteinbergRSRoss A Steinberg
- Byourak ShabaneBSByourak Shabane
- Jennifer NgoJNJennifer Ngo
- Corey OstoCOCorey Osto
- Gustavo GarciaGGGustavo Garcia
- Michaela VeliovaMVMichaela Veliova
- Vaithilingaraja ArumugaswamiVAVaithilingaraja Arumugaswami
Open Access
- 3 February 2025
- journal article
- research article
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (4) , e202403182
Abstract
SARS-CoV-2 can infect cells through endocytic uptake, a process that is targeted by inhibition of lysosomal proteases. However, clinically this approach to treat viral infections has afforded mixed results, with some studies detailing an oral regimen of hydroxychloroquine accompanied by significant off-target toxicities. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here, we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, are 100–150 nm in diameter, and possess a negative surface charge, which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2 WA1 and its Omicron variant in a human lung epithelium model. Organelle-targeted delivery is an effective means to inhibit viral infection.Keywords
Funding Information
- UCLA COVID-19 Emergency Response (OCRC Grant #20-21)
- BU Nano
- UCLA COVID-19 Emergency Response (OCRC Grant #20-21)
- BU Nano
This publication has 86 references indexed in Scilit:
- Nanoformulated Remdesivir with Extremely Low Content of Poly(2‐oxazoline)‐Based Stabilizer for Aerosol Treatment of COVID‐19Macromolecular Bioscience, 2022
- ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egressDevelopmental Cell, 2021
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunityCell, 2021
- Integrative Imaging Reveals SARS-CoV-2-Induced Reshaping of Subcellular MorphologiesCell Host & Microbe, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human PharmacokineticsClinical Pharmacology & Therapeutics, 2020
- Hyperglycemia, hydroxychloroquine, and the COVID‐19 pandemicJournal of Medical Virology, 2020
- Antiviral activities of selected antimalarials against dengue virus type 2 and Zika virusAntiviral Research, 2017
- Prevention of lung cancer recurrence using cisplatin-loaded superhydrophobic nanofiber meshesBiomaterials, 2016
- Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agentCancer Letters, 2012